NFL Biosciences collaborates with the CEA
02 Février 2023 - 5:45PM
NFL Biosciences collaborates with the CEA
Tobacco addiction: NFL Biosciences collaborates
with the CEA to study the mechanism of action of its drug candidate
NFL-101
NFL BIOSCIENCES (Euronext Growth Paris –
FR0014003XT0 – ALNFL), a biopharmaceutical company
developing botanical drugs for the treatment of dependencies and
addictions, announces the implementation of a study, with
the French Alternative Energies and Atomic Energy
Commission (CEA), on the mechanism of action of
its drug candidate NFL-101.
NFL-Biosciences will use the CEA's molecular
imaging resources to better understand the mechanism of action of
NFL 101. NFL-101 is derived from a subcutaneous desensitization
treatment that was developed by the Pasteur Institute against
tobacco allergies in tobacco factory workers. Used over the counter
by a French doctor on more than 10,000 smokers, the repositioned
extract showed promising results in smoking cessation that were
supported by a retrospective study. NFL-101 is a standardized
version for pharmaceutical use.
The study will be conducted by the
Pharmacological Neuroimaging team of the CEA. It will focus on
following, by positron emission tomography (PET) imaging, the
modifications in the cerebral function associated with the
development of tobacco addiction in mice, in order to highlight the
central effects of NFL-101 treatment in this context. The expected
duration of this study is 9 months.
Bruno Lafont, Chief Operating Officer and
co-founder of NFL Biosciences: "This research is intended to better
understand how NFL-101 can act on tobacco dependence. In the
clinical setting, NFL-101 is only administered once or twice, yet
current treatments must be administered daily for 3 months. In the
case of varenicline (Champix®, Chantix®) treatment starts for three
times a day and continues twice a day for many weeks.”
For Nicolas Tournier, pharmacologist,
radiopharmacist and head of the Pharmacological Neuroimaging team
at the CEA: "This project takes full advantage of the potential of
molecular imaging to highlight the effects of drugs on the brain,
particularly in the context of the treatment of tobacco addiction.
The non-invasive and translational nature of the imaging techniques
used could reveal an activity based on communication between the
immune system and the central nervous system, different from the
modes of action of current smoking cessation drugs that target
nicotine receptors.”
The results, which may be the subject of a joint
scientific publication, will complement the CESTO II and PRECESTO
clinical studies with a view to increase the overall attractiveness
of NFL-101 to pharmaceutical companies that may be interested in
licensing it.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company
based in the Montpellier area which develops botanical drug
candidates for the treatment of addictions. NFL Biosciences'
ambition is to bring new, natural, safer and more effective
therapeutic solutions to the entire world population, including
low- and middle-income countries. Its most advanced product, called
NFL-101, is a standardized, nicotine free tobacco leaf extract
protected by two patent families. NFL Biosciences intends to offer
smokers who want to quit a natural, safe, easy-to-administer and
personalized alternative.
NFL Biosciences is also developing NFL-301, a
natural drug candidate for the reduction of alcohol consumption and
has a drug development project for the treatment of cannabis use
disorders.
The shares of NFL Biosciences are listed on
Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at
www.nflbiosciences.com
Contacts
Bruno Lafont – info@nflbiosciences.com - +33 4
11 93 76 67
Agence Calyptus – nflbio@calyptus.net - +33 1 53
65 68 68
- 20230110 - NFLBioscience_CP_CEA_EN - VERSION FINALE
NFL Biosciences (EU:ALNFL)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
NFL Biosciences (EU:ALNFL)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024